Seres Therapeutics Inc (MCRB)

[MiamiGent]

MCRB Ok, news out. It passed!

No action yet but here is my post on ST


MiamiGent
2m

$MCRB It will slowly and gradually rise here in AH.
Wait for tomorrow. News will be out. The "boys" will latch on to this low PPS issue with good news. Tomorrow.
Bullish

[MiamiGent]

MCRB Quote
AS OF 4/26/2023 3:09PM ET
$6.45 +$0.29 (+4.71%)
Volume
4,351,333

https://stockcharts.com/h-sc/ui?s=MCRB

Still waiting for FDA announcement. I was in one not so long ago that came at 11 PM. I'm too old to remember what that stock symbol was, lol

[MiamiGent]

MCRB PDUFA today

Decision announced any time during day- probably after hours. Even very late in the evening

Company Profile
SectorHealth CareOpens in a new window
IndustryBiotechnologyOpens in a new window
Company LocationCambridge, MA
Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is SER-109, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes SER-109 product candidate, which is developed for the treatment of CDI and recurrent CDI; collaboration license agreement with Societe des Produits Nestle S.A. (Nestle) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease; research collaboration and option agreement with AstraZeneca Inc. for research and develop of microbiome in certain cancers and cancer immunotherapies, including research program for SER-401 targeting various cancers. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
www.serestherapeutics.com
0

[MiamiGent]

MCRB countdown to tomorrow's PDUFA. Have you loaded?

https://stockcharts.com/h-sc/ui?s=MCRB

MG

[MiamiGent]

MCRB Wednesday PDUFA

While we wait..

Weekend Music
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171755545

[MiamiGent]

MCRB In today for PDUFA next week.

Have a great weekend, all!

MG

[Extremist223]

=========================

[Extremist223]

No rebuttal? Is this market even worldwide? Or am I on some fake market for just my pc?

[Extremist223]

I don't know why pharma wouldn't short this POS, if they cure recurrent c. diff it's no longer recurrent and so you aren't selling anything. Doesn't seem like the business model works at all.

It's like sellin' food with vitamins still in it when your competitors did a manual extraction and started selling a separate line of vitamin pills.

It's recurrent for a reason!

[swingingRichard]

I'm not saying I would have played it, but using this chart, I'm not all that surprised by the huge move. It's all about the forced state transition bands.

[crudeoil24]

MCRB is a great $$$$$ opportunity.

[crudeoil24]

Current shelf placement closes Monday, and generates over $200M .
Plus we have a huge new life saving drug coming to marketplace.

[ClayTrader]

* * $MCRB Video Chart 08-13-2020 * *

Link to Video - click here to watch the technical chart video

[ClayTrader]

* * $MCRB Video Chart 08-10-2020 * *

Link to Video - click here to watch the technical chart video

[davidsson10]

MCRB Asset Accumulation

[rlangmaid]

This is HUGE... I am an NP so I know!!

[CyrusDaVirus]

Whats the price target here? Yes

[chuckgray]

73k CDI episodes of 2+ recurrences/year in US as studied in current study. Another 100k/year primary recurrence cases being studied in open label extension trial. Will SER-109 eventually be studied and used for the other 439k/year CDI patients in US to prevent any recurrences?

[$treet $inatra]

MCRB discovers immortality = stock quadruples lol

[Golden Cross]

Good grief chief $$$$$$$$$$$$

[crudeoil24]

MCRB @ 19.39 up 317% >

[crudeoil24]

16.95 up 275% in PM. > FDA phase III news!

[crudeoil24]

Seres Therapeutics Phase 3 SER-109 Study Meets Main Endpoint >MCRB
7:06 am ET August 10, 2020 (Dow Jones) Print
By Colin Kellaher

Seres Therapeutics Inc. on Monday said a pivotal phase 3 study of its investigational oral microbiome therapeutic SER-109 for recurrent C. difficile infection met its primary endpoint.

The Cambridge, Mass., developer of biological drugs said SER-109 showed a highly statistically significant 30.2% absolute reduction in the rate of C. difficile infection recurrence compared with placebo, adding that the drug was well tolerated, with a safety profile comparable to placebo.

Seres also said the study's efficacy results exceeded the U.S. Food and Drug Administration's statistical threshold that could allow the single study to fulfill efficacy requirements for a biologics license application, and the company said it plans to meet with the agency to discuss filing for product approval as soon as possible.

C. difficile, an antibiotic-resistant bacterium, is a leading cause of hospital-acquired infection in the U.S.

Shares of Seres, which closed Friday at $4.64, more than tripled to $14.20 in premarket trading Monday.

Write to Colin Kellaher at [e-mail]

[ClayTrader]

* * $MCRB Video Chart 06-29-2019 * *

Link to Video - click here to watch the technical chart video

[Golden Cross]

Rebound continues here

[ClayTrader]

* * $MCRB Video Chart 06-14-2019 * *

Link to Video - click here to watch the technical chart video

[ClayTrader]

* * $MCRB Video Chart 03-11-2019 * *

Link to Video - click here to watch the technical chart video

[go2sleepjj]

Shorting this to the floor

[DONTSELLFROM_FEAR]

10.71 BOL BAND ..SHOULD BOUNCE BACK DOWN FROM THAT...PLUS RSI HIGH = SELL

[napoleanrags]

The MCRiB is back

[MARINO]

In again at $11.30

[protagonist12]

Marino, picking up nickels in front of a bulldozer...

[MARINO]

Come on MCRB lets close green along with markets

[MARINO]

Marino in again $12.65

[MARINO]

Marino out at $14.65

[stocktrademan]

MCRB bullish 10.4375

rsi14 crossup from 30 oversold scan

[MARINO]

Bought some more at $10.98

[MARINO]

Friday selling. Next week we see $12 again..BUY $$

[MARINO]

$ MCRB $ Easy money $ 12.00s next week

[brojazzy]

Hi everyone! Been in since $9.28, love this stock, we should be seeing higher lows for the foreseeable future, good luck everyone!

[MARINO]

Have u checked EARS and CERU

[MARINO]

Good my friend

[keekee]

Instill have 700 shares and my target is 30 cents away. Been a good one since five trading days....$8.92 to $12

[frankvestor8]

Congrats for hitting your target. I'm thinking possible shorts when the rally runs out of steam. Too busy these days. Have yet to read its ER transcript. Have you listened to it or read it? What're the key things. Would be great to know before I find time to read it. Thanks.

[MARINO]

My $11 target almost reach. I'm out $$$

[keekee]

Lol. $1.30 more and I'll hit my one week target. I was looking at next week but it may come anytime now.

[keekee]

Hard to imagine where these idiots and mm shorts are getting the shares to sell. But my target is unchanged at $12.

[keekee]

$12. It was headed straight there like an arrow. Should I have gotten more T $8.90s....you bet!!! But you have to have some heart to look beyond the shorting game here and see the opportunity. It takes some brain work.....

[keekee]

With what I heard on the cc.....you will get stabilization here in the $15 range until new update regard 109. It may see $12 as early as next week.

[keekee]

So far I've bot 3200 between$8.80 and $8.91. Played out well...I was worried I may chase it above $10. Now it is chasing me....lol